Navigation Links
BP and Prostate Problems Drug Effective in Treating PTSD Nightmares

A generic drug already used for high blood pressure and prostate problems has been found to improve// sleep and lessen nightmares in veterans with posttraumatic stress disorder (PTSD).

"This is the first drug that has been demonstrated effective for PTSD nightmares and sleep disruption," said Murray A. Raskind, MD, executive director of the mental health service at the Veterans Affairs Puget Sound Health Care System and lead author of a study appearing April 15 in Biological Psychiatry.

The randomized trial of 40 veterans compared a nightly dose of prazosin (PRAISE-oh-sin) with placebo over eight weeks. Participants continued to take other prescribed medications over the course of the trial.

At the end of the study, veterans randomized to prazosin reported significantly improved sleep quality, reduced trauma nightmares, a better overall sense of well being, and an improved ability to function.

"These nighttime symptoms are heavily troublesome to veterans," said Raskind, who also is director of VA’s VISN 20 (Veterans Integrated Service Network #20) Mental Illness Research, Education and Clinical Centers program (MIRECC). "If you get the nighttime symptoms under control, veterans feel better all around."

Raskind, also a professor of psychiatry and behavioral sciences at the University of Washington, estimates that of the 10 million U.S. veterans and civilians with PTSD, about half have trauma-related nightmares that could be helped with the drug.

Participants were given 1 mg of prazosin per day for the first three days. The dose was gradually increased over the first four weeks to a maximum of 15 mg at bedtime. The average dose of prazosin in the trial was 13.3 mg. By comparison, typical prazosin doses for controlling blood pressure or treating prostate problems range from 3 mg to 30 mg per day in divided doses.

The drug did not affect blood pressure compared to placebo, th ough some participants reported transient dizziness when standing from a sitting position during the first weeks of prazosin titration. Other occasional side effects included nasal congestion, headache, and dry mouth, but these were all minor, according to the authors.

"This drug has been taken by many people for decades," said Raskind. "If there were serious long-term adverse side effects, it is likely we would know about them by now."

The relatively small size of the study was due to the easy availability of this generic drug, Raskind said. "If you are doing a study with a new drug, the only way people can get it is to be in the study. With prazosin, we have approximately 5,000 veterans with a PTSD diagnosis taking it already in the Northwest alone. So we had to find veterans with PTSD who were not [taking it]."

For treating PTSD, prazosin costs 10 to 30 cents a day at VA contract prices. It is not a sedating sleeping pill, emphasized Raskind. "It does not induce sleep. But once you are asleep, you sleep longer and better."

And better sleep can make a big difference. "This drug changes lives," Raskind said. "Nothing else works like prazosin."

Trauma nightmares appear to arise during light sleep or disruption in REM sleep, whereas normal dreams—both pleasant and unpleasant— occur during normal REM sleep. Prazosin works by blocking the brain’s response to the adrenaline-like neurotransmitter norepinephrine. Blocking norepinephrine normalizes and increases REM sleep. In this study, veterans taking prazosin reported that they resumed normal dreaming.

One dose of prazosin works for 6 to 8 hours. Unlike similar drugs, prazosin does not induce tolerance; people can take it for years without increasing the dose. But when veterans stop taking it, Raskind said, the trauma nightmares usually return.

Aside from the VA-funded study he just published, Raskind is working on three large r studies of prazosin. One, a VA cooperative study slated to start this month, will enroll about 300 veterans at 12 VA facilities. The second, a collaborative study with Walter Reed Army Medical Center and Madigan Army Medical Center, will enroll active-duty soldiers who have trauma nightmares. The third study, funded by the National Institute of Mental Health, will look at prazosin in the treatment of civilian trauma PTSD.

Source-Eurekalert
SR/V
'"/>




Related medicine news :

1. Cancer Doctors Okays Controversial Prostate Therapy
2. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
3. New Prostate Cancer Vaccine Shows Promise
4. Hormone Therapy applicable for Prostate Cancer
5. Prostate cancer and Vitamins
6. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
7. Early Detection Of Prostate Cancer
8. Awareness increase Prostate cancer detection
9. Better Prostate Cancer Test
10. Stopping Prostate Cancer from Spreading
11. Drug might prevent Prostate Cancer Spread
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/8/2016)... , ... December 08, 2016 , ... ... Chester County, a Property owned by an affiliate of Seavest, has won a ... Penn Medicine Southern Chester County ambulatory care center (ACC) was named “Best New ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... Somerset, N.J. (PRWEB) , ... December 08, 2016 ... ... advanced delivery technologies and development solutions for drugs, biologics and consumer health products, ... The PSCI was set up in 2006 as a non-profit organization to unite ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... surgery as possible. With this in mind, SIGVARIS has created a new line ... clot) during bed rest and provide the benefits of graduated compression when transitioning ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dianne Michael Insurance ... in Hamilton County, is embarking on a charity drive with the aim of ... homes for orphaned or neglected senior dogs in the Cincinnati region, and LuvFurMutts ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Japan , Dec. 9, 2016 Mitsubishi ... ; President & Representative Director, CEO: Dr. Masayuki ... amyotrophic lateral sclerosis (ALS) given edaravone intravenously in 10-14 ... loss as measured by the ALS Functional Rating Scale-Revised ... International Symposium on ALS/MND in Dublin, ...
(Date:12/9/2016)... Research and Markets has announced the addition of the ... ... travel vaccines market to grow at a CAGR of 6.83% during ... and the growth prospects of the global travel vaccines market for ... generated from the sales of various vaccines administered to actively immunize ...
(Date:12/9/2016)... DIEGO , Dec. 9, 2016  Forge ... Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: ... targeting ,LpxC, for the treatment of bacterial infections ... has been recognized as an attractive antibacterial target ... a lack of suitable chemical starting points has ...
Breaking Medicine Technology: